Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Double-blind, Active Controlled and Open-label, Single-arm

    Summary
    EudraCT number
    2021-005504-36
    Trial protocol
    DK   BE  
    Global end of trial date
    05 Oct 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    09 Mar 2025
    First version publication date
    09 Mar 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ABNCoV2-03
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT05329220
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Bavarian Nordic A/S
    Sponsor organisation address
    Philip Heymans Alle 3, Hellerup, Denmark, 2900
    Public contact
    clinical-mailbox, Bavarian Nordic GmbH, clinical-mailbox@bavarian-nordic.com
    Scientific contact
    clinical-mailbox, Bavarian Nordic GmbH, clinical-mailbox@bavarian-nordic.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    11 Dec 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    15 Mar 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    05 Oct 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this phase 3 trial is to assess the non-inferiority, or superiority of vaccination with ABNCoV2 compared to Comirnaty in terms of neutralizing antibodies against the SARS CoV 2 index virus (Wuhan wild type isolate). This objective will be carried out in the randomized, double-blind component (Part A), in Cohort 1 (adult subjects who previously completed primary vaccination only) and Cohort 2 (adult subjects who have received 1 booster vaccination after a primary regimen) simultaneously. If the non-inferiority margin is met, superiority comparison will be carried out in the same cohort with the same type I error level. If for any reason, the minimum sample size of 400 is not met in one cohort, data from that cohort will be summarized descriptively.
    Protection of trial subjects
    If an event occurs which fulfills the trial halting rules (see Section 13.3.2 for further details), the DMC will review the event in a timely manner and agree whether to recommend halting or terminating the trial participation of the affected subject(s) and/or the trial as a whole. If the trial as a whole or participation of specific subjects is halted, the DMC also will decide if and when to recommend resuming the trial or subject participation in it. The events or criteria listed below would trigger a DMC review to determine whether a temporary halting or termination for the trial as a whole is warranted: 1.) A serious AESI or other SAE with an at least reasonable possibility of a causal relationship to the administration of trial vaccine 2.) An unexpected Grade 3 or higher adverse event (e.g., a systemic reaction or lab toxicity) with at least a reasonable possibility of a causal relationship to the administration of trial vaccine 3.) Any case of myocarditis or pericarditis in temporal association to the administration of trial vaccine The Medical Monitor or safety physician will review cases of Grade 3 or higher adverse events at least weekly. Any issues identified during this review can be brought to the DMC for review.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    30 Aug 2022
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 378
    Country: Number of subjects enrolled
    Denmark: 244
    Country: Number of subjects enrolled
    United States: 3583
    Worldwide total number of subjects
    4205
    EEA total number of subjects
    622
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    3067
    From 65 to 84 years
    1138
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    At least 500 subjects were to be enrolled into Part A of this trial, and approximately 3000 subjects were to be enrolled into Part B.

    Pre-assignment
    Screening details
    Enrollment for Part A and Part B occurred simultaneously and enrollment was based on prior SARS-CoV-2 experience, with Cohort 1 including an authorized primary vaccination regimen; and Cohort 2 including an authorized primary vaccination regimen with a booster vaccination.

    Period 1
    Period 1 title
    Active Trial and 6-month Follow Up (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Part A Cohort 1 ABNCoV2
    Arm description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by intramuscular injection on Day 1
    Arm type
    Experimental

    Investigational medicinal product name
    ABNCoV2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    A single dose of 100 ug of ABNCoV2 will be administere. Vials of ABNCoV2 will contain at least 100 ug in 0.5 mL.

    Arm title
    Part A Cohort 1 Comirnaty
    Arm description
    Subjects who previously completed primary vaccination 30ug Comirnaty by intramuscular injection on Day 1
    Arm type
    Active comparator

    Investigational medicinal product name
    Comirnaty
    Investigational medicinal product code
    Other name
    INN-tozinameran, tozinameran/famtozinameran, raxtozinameran, bretovameran
    Pharmaceutical forms
    Suspension for injection, Suspension for injection in multidose container
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Comirnaty is commercially available and may be a single dose vial containing 1 dose of 0.3 mL containing 30 ug of tozinameran or a multidose vial containing 6 doses of 0.3 mL with each containing 30 ug of tozinameran. 30 ug will be administered intramuscularly.

    Arm title
    Part A Cohort 2 ABNCoV2
    Arm description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by intramuscular injection on Day 1
    Arm type
    Experimental

    Investigational medicinal product name
    ABNCoV2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    A single dose of 100 ug of ABNCoV2 will be administere. Vials of ABNCoV2 will contain at least 100 ug in 0.5 mL.

    Arm title
    Part A Cohort 2 Comirnaty
    Arm description
    Subjects who previously completed primary vaccination plus 1 booster 30ug Comirnaty by intramuscular injection on Day 1
    Arm type
    Active comparator

    Investigational medicinal product name
    Comirnaty
    Investigational medicinal product code
    Other name
    INN-tozinameran, tozinameran/famtozinameran, raxtozinameran, bretovameran
    Pharmaceutical forms
    Suspension for injection, Suspension for injection in multidose container
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Comirnaty is commercially available and may be a single dose vial containing 1 dose of 0.3 mL containing 30 ug of tozinameran or a multidose vial containing 6 doses of 0.3 mL with each containing 30 ug of tozinameran. 30 ug will be administered intramuscularly.

    Arm title
    Part B Cohort 1 ABNCoV2
    Arm description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by intramuscular injection on Day 1
    Arm type
    Experimental

    Investigational medicinal product name
    ABNCoV2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    A single dose of 100 ug of ABNCoV2 will be administere. Vials of ABNCoV2 will contain at least 100 ug in 0.5 mL.

    Arm title
    Part B Cohort 2 ABNCoV2
    Arm description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by intramuscular injection on Day 1
    Arm type
    Experimental

    Investigational medicinal product name
    ABNCoV2
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    A single dose of 100 ug of ABNCoV2 will be administere. Vials of ABNCoV2 will contain at least 100 ug in 0.5 mL.

    Number of subjects in period 1
    Part A Cohort 1 ABNCoV2 Part A Cohort 1 Comirnaty Part A Cohort 2 ABNCoV2 Part A Cohort 2 Comirnaty Part B Cohort 1 ABNCoV2 Part B Cohort 2 ABNCoV2
    Started
    34
    34
    277
    277
    1438
    2145
    Completed
    34
    33
    272
    273
    1285
    2009
    Not completed
    0
    1
    5
    4
    153
    136
         Adverse event, serious fatal
    -
    -
    1
    1
    -
    1
         Consent withdrawn by subject
    -
    -
    1
    1
    34
    35
         Physician decision
    -
    -
    -
    -
    2
    2
         Adverse event, non-fatal
    -
    -
    -
    -
    2
    1
         Moved out of country
    -
    -
    1
    -
    -
    -
         Out of town for extended period
    -
    -
    -
    -
    1
    -
         Sponsor Decision
    -
    -
    -
    -
    -
    1
         Lost to follow-up
    -
    1
    2
    2
    113
    89
         Refused to attend final visits, various reasons
    -
    -
    -
    -
    -
    6
         Protocol deviation
    -
    -
    -
    -
    1
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Part A Cohort 1 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by intramuscular injection on Day 1

    Reporting group title
    Part A Cohort 1 Comirnaty
    Reporting group description
    Subjects who previously completed primary vaccination 30ug Comirnaty by intramuscular injection on Day 1

    Reporting group title
    Part A Cohort 2 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by intramuscular injection on Day 1

    Reporting group title
    Part A Cohort 2 Comirnaty
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 30ug Comirnaty by intramuscular injection on Day 1

    Reporting group title
    Part B Cohort 1 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by intramuscular injection on Day 1

    Reporting group title
    Part B Cohort 2 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by intramuscular injection on Day 1

    Reporting group values
    Part A Cohort 1 ABNCoV2 Part A Cohort 1 Comirnaty Part A Cohort 2 ABNCoV2 Part A Cohort 2 Comirnaty Part B Cohort 1 ABNCoV2 Part B Cohort 2 ABNCoV2 Total
    Number of subjects
    34 34 277 277 1438 2145 4205
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    34 34 247 249 1147 1356 3067
        From 65-84 years
    0 0 30 28 291 789 1138
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    34.4 ( 13.44 ) 32.2 ( 11.67 ) 42.8 ( 16.4 ) 41.8 ( 15.91 ) 48.2 ( 15.6 ) 54.5 ( 15.73 ) -
    Gender categorical
    Units: Subjects
        Female
    15 12 133 135 813 1210 2318
        Male
    19 22 144 142 625 935 1887
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    0 1 2 3 623 593 1222
        Not Hispanic or Latino
    34 33 274 274 795 1523 2933
        Unknown or Not Reported
    0 0 1 0 20 29 50
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0 0 6 17 23
        Asian
    0 0 2 1 27 59 89
        Native Hawaiian or Other Pacific Islander
    0 0 0 0 0 3 3
        Black or African American
    0 0 0 1 439 469 909
        White
    33 34 272 273 911 1521 3044
        More than one race
    0 0 0 1 14 28 43
        Unknown or Not Reported
    1 0 3 1 41 48 94
    Region of Enrollment
    Units: Subjects
        Belgium
    24 26 161 167 0 0 378
        United States
    0 0 0 0 1438 2145 3583
        Denmark
    10 8 116 110 0 0 244

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Part A Cohort 1 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by intramuscular injection on Day 1

    Reporting group title
    Part A Cohort 1 Comirnaty
    Reporting group description
    Subjects who previously completed primary vaccination 30ug Comirnaty by intramuscular injection on Day 1

    Reporting group title
    Part A Cohort 2 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by intramuscular injection on Day 1

    Reporting group title
    Part A Cohort 2 Comirnaty
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 30ug Comirnaty by intramuscular injection on Day 1

    Reporting group title
    Part B Cohort 1 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by intramuscular injection on Day 1

    Reporting group title
    Part B Cohort 2 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by intramuscular injection on Day 1

    Primary: Neutralizing Antibody Titers Against the SARS-CoV-2 Index Virus (Wuhan Wild Type Isolate) at 2 Weeks After Trial Vaccination [Time Frame: 2 weeks after the single trial vaccination occurring on Day 1]

    Close Top of page
    End point title
    Neutralizing Antibody Titers Against the SARS-CoV-2 Index Virus (Wuhan Wild Type Isolate) at 2 Weeks After Trial Vaccination [Time Frame: 2 weeks after the single trial vaccination occurring on Day 1] [1]
    End point description
    The primary endpoint was SARS-CoV-2 index virus (Wuhan wild type isolate) neutralizing antibodies assessed at 2 weeks after trial vaccination, for subjects in the Immunogenicity Analysis Sets in Part A Cohort 1 (adult subjects who previously completed primary vaccination at least 3 months prior to the screening visit) and Part A Cohort 2 (adult subjects who have completed primary vaccination and have received 1 booster vaccination).
    End point type
    Primary
    End point timeframe
    2 weeks after the single trial vaccination occurring on Day 1
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Analyses were performed only on the groups included in Part A Cohort 1 and 2 of the protocol. Part B of the trial was open-label ABNCoV2 for Safety Analyses only, as there was no comparator.
    End point values
    Part A Cohort 1 ABNCoV2 Part A Cohort 1 Comirnaty Part A Cohort 2 ABNCoV2 Part A Cohort 2 Comirnaty
    Number of subjects analysed
    34
    33
    267
    261
    Units: titer
        geometric mean (confidence interval 95%)
    1018.1 (621.1 to 1669)
    1060.6 (708.2 to 1588.3)
    1259 (1125.3 to 1408.4)
    1619.6 (1485.9 to 1765.4)
    Statistical analysis title
    Non-Inferiority Test of Part A Cohort 1
    Statistical analysis description
    Formal hypothesis testing was performed due to having at least 400 evaluable subjects with primary endpoint data available at baseline and at 2 weeks after trial vaccination. The null hypothesis is that ABNCoV2 is inferior to Comirnaty and will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    Comparison groups
    Part A Cohort 1 ABNCoV2 v Part A Cohort 1 Comirnaty
    Number of subjects included in analysis
    67
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [2]
    P-value
    = 0.635 [3]
    Method
    Mixed models analysis
    Parameter type
    Geometric Mean Ratio
    Point estimate
    0.89
    Confidence interval
         level
    97.5%
         sides
    2-sided
         lower limit
    0.5
         upper limit
    1.57
    Notes
    [2] - The success criterion for the null hypothesis that ABNCoV2 is inferior to Comirnaty will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    [3] - P-value corresponds to Cohort 1 ABNCoV2 comparison to Cohort 1 Comirnaty
    Statistical analysis title
    Non-Inferiority Test of Part A Cohort 2
    Statistical analysis description
    Formal hypothesis testing was performed due to having at least 400 evaluable subjects with primary endpoint data available at baseline and at 2 weeks after trial vaccination. The null hypothesis is that ABNCoV2 is inferior to Comirnaty and will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    Comparison groups
    Part A Cohort 2 ABNCoV2 v Part A Cohort 2 Comirnaty
    Number of subjects included in analysis
    528
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [4]
    P-value
    = 0.0002 [5]
    Method
    Mixed models analysis
    Parameter type
    Geometric Mean Ratio
    Point estimate
    0.8
    Confidence interval
         level
    97.5%
         sides
    2-sided
         lower limit
    0.7
         upper limit
    0.92
    Notes
    [4] - The success criterion for the null hypothesis that ABNCoV2 is inferior to Comirnaty will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    [5] - P-value corresponds to Cohort 2 ABNCoV2 comparison to Cohort 2 Comirnaty

    Secondary: Neutralizing Antibody Titers Against the SARS-CoV-2 Variants of Concern (Omicron Variant BA.4/BA.5) at 2 Weeks After Trial Vaccination

    Close Top of page
    End point title
    Neutralizing Antibody Titers Against the SARS-CoV-2 Variants of Concern (Omicron Variant BA.4/BA.5) at 2 Weeks After Trial Vaccination [6]
    End point description
    The secondary endpoint was SARS-CoV-2 variants of concern (Omicron Variant BA.4/BA.5) pseudovirus neutralizing antibodies assessed at 2 weeks after trial vaccination, for subjects in the Immunogenicity Analysis Sets in Part A Cohort 1 (adult subjects who previously completed primary vaccination at least 3 months prior to the screening visit) and Part A Cohort 2 (adult subjects who have completed primary vaccination and have received 1 booster vaccination.
    End point type
    Secondary
    End point timeframe
    2 weeks after the single trial vaccination occurring on Day 1
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Analyses were performed only on the groups included in Part A Cohort 2 of the protocol as the others did not meet the sample size requirement to be included. Part B of the trial was open-label ABNCoV2 for Safety Analyses only, as there was no comparator.
    End point values
    Part A Cohort 1 ABNCoV2 Part A Cohort 1 Comirnaty Part A Cohort 2 ABNCoV2 Part A Cohort 2 Comirnaty
    Number of subjects analysed
    0 [7]
    0 [8]
    265
    260
    Units: titre
        geometric mean (confidence interval 95%)
    ( to )
    ( to )
    17112.6 (14775.8 to 19818.9)
    23506.3 (20794.5 to 26571.7)
    Notes
    [7] - Due to not meeting the primary objective criteria, Part A Cohort 1 was not analyzed.
    [8] - Due to not meeting the primary objective criteria, Part A Cohort 1 was not analyzed.
    Statistical analysis title
    Non-Inferiority Test of Part A Cohort 2 BA.4/BA.5
    Statistical analysis description
    Formal hypothesis testing was performed due to meeting the primary endpoint success criterion in Cohort 2. The null hypothesis is that ABNCoV2 is inferior to Comirnaty and will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    Comparison groups
    Part A Cohort 2 ABNCoV2 v Part A Cohort 2 Comirnaty
    Number of subjects included in analysis
    525
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [9]
    P-value
    = 0.0008 [10]
    Method
    Mixed models analysis
    Parameter type
    Geometric Mean Ratio
    Point estimate
    0.76
    Confidence interval
         level
    97.5%
         sides
    2-sided
         lower limit
    0.64
         upper limit
    0.91
    Notes
    [9] - The success criterion for the null hypothesis that ABNCoV2 is inferior to Comirnaty will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    [10] - P-value corresponds to Cohort 2 ABNCoV2 comparison to Cohort 2 Comirnaty for Omicron variant BA.4/BA.5

    Secondary: Neutralizing Antibody Titers Against the SARS-CoV-2 Variants of Concern (Omicron Variant XBB.1.5) at 2 Weeks After Trial Vaccination

    Close Top of page
    End point title
    Neutralizing Antibody Titers Against the SARS-CoV-2 Variants of Concern (Omicron Variant XBB.1.5) at 2 Weeks After Trial Vaccination [11]
    End point description
    The secondary endpoint was SARS-CoV-2 variants of concern (Omicron Variant XBB.1.5) virus neutralizing antibodies assessed at 2 weeks after trial vaccination, for subjects in the Immunogenicity Analysis Sets in Part A Cohort 1 (adult subjects who previously completed primary vaccination at least 3 months prior to the screening visit) and Part A Cohort 2 (adult subjects who have completed primary vaccination and have received 1 booster vaccination.
    End point type
    Secondary
    End point timeframe
    2 weeks after the single trial vaccination occurring on Day 1
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Analyses were performed only on the groups included in Part A Cohort 2 of the protocol as the others did not meet the sample size requirement to be included. Part B of the trial was open-label ABNCoV2 for Safety Analyses only, as there was no comparator.
    End point values
    Part A Cohort 2 ABNCoV2 Part A Cohort 2 Comirnaty
    Number of subjects analysed
    265
    260
    Units: titre
        geometric mean (confidence interval 95%)
    54.7 (48.9 to 61.3)
    81.3 (73.1 to 90.4)
    Statistical analysis title
    Non-Inferiority Test of Part A Cohort 2 XBB.1.5
    Statistical analysis description
    Formal hypothesis testing was performed due to meeting the primary endpoint success criterion in Cohort 2. The null hypothesis is that ABNCoV2 is inferior to Comirnaty and will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    Comparison groups
    Part A Cohort 2 ABNCoV2 v Part A Cohort 2 Comirnaty
    Number of subjects included in analysis
    525
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [12]
    P-value
    < 0.0001 [13]
    Method
    Mixed models analysis
    Parameter type
    Geometric Mean Ratio
    Point estimate
    0.69
    Confidence interval
         level
    97.5%
         sides
    2-sided
         lower limit
    0.59
         upper limit
    0.81
    Notes
    [12] - The success criterion for the null hypothesis that ABNCoV2 is inferior to Comirnaty will be rejected if the ratio of the GMTs for ABNCoV2 versus Comirnaty is within the non-inferiority margin of 0.67; that is, the lower bound of the 2-sided 97.5% CI of the GMT ratio is >=0.67.
    [13] - P-value corresponds to Cohort 2 ABNCoV2 comparison to Cohort 2 Comirnaty for Omicron Variant XBB.1.5.

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Overall trial from vaccination through final follow-up visit at Day 182
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    25.0
    Reporting groups
    Reporting group title
    Part A Cohort 1 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by subcutaneous injection on Day 1

    Reporting group title
    Part A Cohort 1 Comirnaty
    Reporting group description
    Subjects who previously completed primary vaccination 30ug Comirnaty by subcutaneous injection on Day 1

    Reporting group title
    Part A Cohort 2 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by subcutaneous injection on Day 1

    Reporting group title
    Part A Cohort 2 Comirnaty
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 30ug Comirnaty by subcutaneous injection on Day 1

    Reporting group title
    Part B Cohort 1 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination 100ug ABNCoV2 by subcutaneous injection on Day 1

    Reporting group title
    Part B Cohort 2 ABNCoV2
    Reporting group description
    Subjects who previously completed primary vaccination plus 1 booster 100ug ABNCoV2 by subcutaneous injection on Day 1

    Serious adverse events
    Part A Cohort 1 ABNCoV2 Part A Cohort 1 Comirnaty Part A Cohort 2 ABNCoV2 Part A Cohort 2 Comirnaty Part B Cohort 1 ABNCoV2 Part B Cohort 2 ABNCoV2
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 34 (0.00%)
    3 / 277 (1.08%)
    7 / 277 (2.53%)
    23 / 1438 (1.60%)
    49 / 2145 (2.28%)
         number of deaths (all causes)
    0
    0
    1
    1
    0
    1
         number of deaths resulting from adverse events
    0
    0
    1
    1
    0
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Acoustic neuroma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain cancer metastatic
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Breast cancer metastatic
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endometrial adenocarcinoma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung cancer metastatic
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung neoplasm malignant
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oropharyngeal squamous cell carcinoma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    2 / 2145 (0.09%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small cell carcinoma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Arterial occlusive disease
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertension
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Systemic inflammatory response syndrome
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Abnormal uterine bleeding
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pelvic organ prolapse
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute respiratory failure
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleuritic pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bipolar disorder
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Completed suicide
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    1 / 277 (0.36%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Delirium tremens
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Major depression
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Suicide attempt
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    1 / 277 (0.36%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Astrovirus test positive
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Cervical vertebral fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Foot fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Humerus fracture
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Joint dislocation
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural haematoma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin laceration
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal cord injury cervical
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound necrosis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute coronary syndrome
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    2 / 1438 (0.14%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    3 / 2145 (0.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bradycardia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Coronary artery disease
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    2 / 2145 (0.09%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial ischaemia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocarditis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebral infarction
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    2 / 1438 (0.14%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Migraine
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Presyncope
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    2 / 1438 (0.14%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    1 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood loss anaemia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo positional
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peptic ulcer haemorrhage
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Diabetic foot
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash maculo-papular
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    End stage renal disease
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Obstructive nephropathy
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Intervertebral disc degeneration
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal stenosis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Abdominal wall abscess
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthritis bacterial
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    2 / 2145 (0.09%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dengue fever
         subjects affected / exposed
    1 / 34 (2.94%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Helicobacter infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intervertebral discitis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    0 / 1438 (0.00%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestine infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Liver abscess
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pelvic inflammatory disease
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Perirectal abscess
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    0 / 2145 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    2 / 2145 (0.09%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    1 / 1438 (0.07%)
    2 / 2145 (0.09%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    3 / 2145 (0.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyperkalaemia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    1 / 277 (0.36%)
    2 / 1438 (0.14%)
    3 / 2145 (0.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 34 (0.00%)
    0 / 34 (0.00%)
    0 / 277 (0.00%)
    0 / 277 (0.00%)
    0 / 1438 (0.00%)
    1 / 2145 (0.05%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Part A Cohort 1 ABNCoV2 Part A Cohort 1 Comirnaty Part A Cohort 2 ABNCoV2 Part A Cohort 2 Comirnaty Part B Cohort 1 ABNCoV2 Part B Cohort 2 ABNCoV2
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    6 / 34 (17.65%)
    4 / 34 (11.76%)
    40 / 277 (14.44%)
    47 / 277 (16.97%)
    36 / 1438 (2.50%)
    125 / 2145 (5.83%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 34 (8.82%)
    1 / 34 (2.94%)
    11 / 277 (3.97%)
    10 / 277 (3.61%)
    11 / 1438 (0.76%)
    16 / 2145 (0.75%)
         occurrences all number
    3
    1
    11
    10
    11
    17
    Infections and infestations
    COVID-19
         subjects affected / exposed
    1 / 34 (2.94%)
    1 / 34 (2.94%)
    17 / 277 (6.14%)
    14 / 277 (5.05%)
    36 / 1438 (2.50%)
    125 / 2145 (5.83%)
         occurrences all number
    1
    1
    17
    14
    36
    125
    Nasopharyngitis
         subjects affected / exposed
    2 / 34 (5.88%)
    0 / 34 (0.00%)
    15 / 277 (5.42%)
    21 / 277 (7.58%)
    5 / 1438 (0.35%)
    13 / 2145 (0.61%)
         occurrences all number
    2
    0
    15
    21
    5
    13
    Pharyngitis
         subjects affected / exposed
    1 / 34 (2.94%)
    2 / 34 (5.88%)
    2 / 277 (0.72%)
    3 / 277 (1.08%)
    3 / 1438 (0.21%)
    5 / 2145 (0.23%)
         occurrences all number
    1
    2
    2
    3
    3
    5

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    01 Apr 2022
    The protocol Edition 2.0 has been created to implement and incorporate administrative and clerical revisions and to add demographics collection at the screening visit within the schedule of events.
    01 Jun 2022
    The protocol Edition 3.0 was created to implement a title change and major design changes to the previous edition. Extensive changes included: The addition of the two-part trial design; Separation of Cohort 1 and 2 based on previous vaccination schedule; Comparator vaccine sourcing changed from routine access to blinded trial vaccine; Randomization ratio changed from 3:1 to 1:1; Part B Component including immunogenicity subset; Non-inferiority testing to be completed simultaneously in both cohorts in Part A; Comparison between Part A and Part B added; Homologous primary vaccination cohort removed; Prior booster vaccination amount limited to 1; Inclusion criteria for prior vaccination changed from 6 months to 3 months; Exclusion limited to COVID-19 infection in last 3 months (reduced from 6 months); Trial population to include 1000 subjects ≥65 years of age; Trial schedule: Visit 1 and day of vaccination combined (no need to allow time for routine access); Safety data updated to be consistent with Topline Interim Clinical Study Report; T-cell data added to phase 2 results in Background section; Gate-keeping approach to multiplicity described; Seropositivity (≥2-fold and ≥4-fold increase) added as supportive analyses; Unblinding process added; COVID-19 resulting in critical illness added to severe COVID-19 as cases to be reviewed by DMC; Regions limited to Denmark, Belgium, US; Editorial updates.
    09 Jun 2022
    The protocol Edition 4.0 has been created to implement changes to the previous edition. These changes include: Removal of ECG during screening; Addition of text indicating an ECG may be performed as needed during an unscheduled visit.
    14 Jun 2022
    The protocol Edition 5.0 has been created to implement and incorporate administrative and clerical revisions.
    28 Jul 2022
    The protocol Edition 6.0 has been created to implement and incorporate changes as requested by the US FDA. These changes include: Additional clerical text about timing of safety follow-up; Addition of reporting for medically attended adverse events; Details around shipping and storage of the comparator product; Addition of an ECG at baseline; Collection of Adverse events of Special interest; Updates to the DMC stopping rules.
    15 Feb 2023
    The protocol Edition 7.0 has been created to implement and incorporate revisions as requested by EMA. These changes include: Clarification on the timing of the previous vaccination schedule or vaccination plus booster schedule; Specification on the number of sites in each country; New exclusion criteria; Sample collection for nucleocapsid protein antibody testing; Transition of responsibilities; Study completion definition added; Clarity for solicited AE collection; Methods for secondary endpoint adjustments for multiplicity further specified; Addition of prior vaccination regimen as a subgroup analysis; Time of analysis and reporting.
    23 Jun 2023
    The protocol Edition 8.0 has been created to implement changes related to the analysis of nucleocapsid protein results.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 23:25:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA